Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

Buch, M. H., Bhatt, D. L., Charles-Schoeman, C., Giles, J. T., Mikuls, T., Koch, G. G., Ytterberg, S., Nagy, E., Jo, H., Kwok, K., Connell, C. A., Masri, K. R., & Yndestad, A. (2024). Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open, 10(2), e003912. https://doi.org/10.1136/rmdopen-2023-003912
Authors:
Maya H Buch
Deepak L Bhatt
Christina Charles-Schoeman
Jon T Giles
Ted Mikuls
Gary G Koch
Steven Ytterberg
Edward Nagy
Hyejin Jo
Kenneth Kwok
Carol A Connell
Karim Richard Masri
Arne Yndestad
Affiliated Authors:
Jon T Giles
Columbia Affiliation:
Subjects:
Arthritis, Rheumatoid (MeSH)
Heart Failure (MeSH)
Myocardial Infarction (MeSH)
Pyrimidines (MeSH)
Venous Thromboembolism (MeSH)
Author Keywords:
antirheumatic agents
cardiovascular diseases
therapeutics
arthritis, rheumatoid
tumor necrosis factor inhibitors
elink
Publication Type:
Article
Unique ID:
10.1136/rmdopen-2023-003912
PMID:
38609322
DOI:
10.1136/rmdopen-2023-003912
Journal:
RMD Open
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: